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Summary An enyme-linked immunosorbent assay (ELISA) has been developed for measuring the in vivo
binding of a hexafluorinated 2-nitroimidazole (CCI-103F) in tumour tissue biopsies. The binding of CCI-103F
is believed to reflect the presence of hypoxia in tumours. The ELISA provides a sensitive and convenient
method of measuring CCI-103F binding which does not require the injection of radioactive reagents. The
ELISA is based on reagents prepared from synthetic antigens formed by the reductive activation and binding
of CCI-103F to proteins in novel test tube experiments. Calibration of the ELISA involved comparing the
ELISA with the radioactivity contained either in protein-CCI-103F adducts formed in vitro with tritiated
CCI-103F or in tissues isolated from a tumour-bearing dog which had been injected with tritium-labelled
CCI-103F. The two approaches to calibration are compared. The scope and limitation of the ELISA for
measuring the binding of CCI-103F is discussed and an example of the application of the ELISA to measuring
changes in tumour hypoxia in canine patients undergoing fractionated radiation therapy is presented.
The role of hypoxia in increasing radioresistance in experi-
mental tumours is well documented (Powers & Tolmach,
1963; see review by Moulder & Rockwell, 1987). Its impor-
tance in human tumour treatment has been long suspected
(Mottram, 1936; Thomlinson & Gray, 1955), but the routine
measurement of hypoxia in human tumours has been difficult
to achieve. One approach which shows promise (Chapman,
1991) is based on the observation that 2-nitroimidazole com-
pounds are metabolically activated and bind to hypoxic
mammalian cells (Varghese et al., 1976; Varghese & Whit-
more, 1980). Generally speaking, the rate of binding in-
creases over the same oxygen concentration range in which
radiation resistance is significantly increased (Franko et al.,
1987). A variety of techniques for detecting the binding of
suitably labelled 2-nitroimidazoles to hypoxic tumour cells
have been clinically tested, including autoradiography (Urta-
sun et al., 1986), positron emission transaxial tomography
('8F-PETT) (Koh et al., 1992) and single-photon emission
computed tomography ('25I-SPECT) (Mannan et al., 1991). A
non-invasive '9F magnetic resonance spectroscopy (MRS)
approach using the fluorinated 2-nitroimidazole, CCI-103F,
has been developed and tested in experimental tumours (Li et
al., 1991; Maxwell et al., 1989; Raleigh et al., 1986, 1991).
Technically simple, immunochemical alteratives to these tech-
niques became feasible with the preparation of polyclonal
antibodies to an antigen formed by the binding of CCI-103F
to proteins under hypoxic conditions (Raleigh et al., 1987).
Initially, immunohistochemistry combined with morphomet-
ric analysis was used to provide a measure of the fraction of
cells in sections of tumour tissue which bound CCI-103F
(Cline et al., 1990). However, for repetitive measurements of
tumour hypoxia the immunohistochemical technique was
relatively slow and labour intensive. Enzyme-linked immuno-
sorbent assay (ELISA) and fluorescence-activated cell sorting
(Hodgkiss et al., 1991) were possible alternatives. These tech-
niques give up the spatial resolution of the immunohis-
tochemical approach but maintain the dependence on cellular
biochemistry and could provide convenient measures of
hypoxia marker binding for use in multiple biopsy samples.
Preliminary studies indicated the possible usefulness of the
ELISA approach (Raleigh et al., 1992). Details of the ELISA
approach to measuring tumour hypoxia and its application
to the measurement of hypoxia in spontaneous canine
tumours are reported here.
Materials and methods
The hypoxia marker, 1-[2-hydroxy-3-(1,1,1,3,3,3-hexafluoro-
isopropoxy)propyl]-2-nitroimidazole (CCI-103F), its tritium-
labelled analogue ([3H]CCI-103F) (Raleigh et al., 1986, 1991)
and rabbit polyclonal antibodies to haemocyanin-bound
CCI-103F were prepared as described previously (Raleigh et
al., 1987). Bovine serum albumin (BSA, fatty acid and
globulin free), goat anti-rabbit IgG conjugated to alkaline
phosphatase, phenylmethylsulphonyl fluoride (PMSF), 5,5'-
dithiobis(2-nitrobenzoic acid) (Ellman's reagent) and the
chromogenic substrates for alkaline phosphatase (Sigma 104
Phosphatase Substrate) were purchased from Sigma. Pro-
teinase K (T. Album, lyophilised), collagenase, elastase,
hyaluronidase and DNA phosphodiesterase were purchased
from Boehringer Mannheim. A standard bicinchoninic acid
assay kit for protein (BCA) was obtained from Pierce and
calibrated against BSA. Corning sterile 96-well polystyrene
microtitre Easy Wash plates were used for ELISA. Becton
Dickinson Falcon 3911 U-bottom 96-well polyvinyl mic-
rotitre plates were used for antigen-antibody pre-
equilibrations.
Thin-layer chromatography oflipid tissue components
Liver tissue or tumour tissue homogenates (0.65 g of a 4:1
buffer/tissue mixture) containing tissue-bound [3H]CCI-103F
(see below) were separately mixed with 8.0 ml of a 2:1
chloroform-methanol mixture and the mixtures centrifuged
at 2000 r.p.m. in a Beckman GPR table-top centrifuge. The
organic layer from each sample was back-extracted with
water and the organic layer drawn off and taken to dryness
in vacuo. The residues were taken up in a small volume of
chloroform for subsequent thin-layer chromatography (TLC)
analysis.
The pellet formed upon centrifugation of the proteinase K
digest of 0.5 ml of [3H]CCI-103F-labelled liver homogenate
(see below) was dissolved in a small volume of chloroform
for TLC analysis. The supernatant (1.0 ml) over the pro-
teinase K pellet was extracted with 2 x 3 ml of a 2: 1
chloroform-methanol mixture, the extract back-extracted
with water and the organic phase taken to dryness and
analysed by TLC. Two TLC solvent systems were used: (a)
chloroform-methanol-water (65:25:4) and (b) chloroform-
methanol (95:7). Samples of the extracts were spotted at the
origin of TLC plates, which were then developed in a
solvent-saturated chamber. The plates were air-dried and
sprayed with 50% aqueous sulphuric acid. Upon heating, the
plates developed charred spots at locations containing lipids.
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The plates were cut into 0.5 cm strips and the tritium content
of the strips measured by adding them to 1Oml of Scin-
tiVerse II (Fisher) in scintillation vials and counting the vials
by means of a Beckman Model LS 5000 TA scintillation
counter.
Preparation oftissue-bound CCI-103F calibration standard
The calibration method for the ELISA was based on parallel
ELISA and scintillation counting measurements of the
amount of tritium-labelled CCI-103F covalently bound in
vivo to canine tumour or liver tissues. A preliminary account
of the in vivo labelling procedure has been reported (Raleigh
et al., 1992). Briefly, a 0.9% saline solution containing
tritiated CCI-103F (specific activity 9.87 iLCi mg-') was
injected as an infusion of Omin duration into the cephalic
vein of a tumour-bearing, 25.5 kg dog which was scheduled
for euthanasia. The whole-body concentration of CCI-103F
was approximately 118 pmol kg-' of body weight. Liver and
tumour tissues were collected 24 h later at autopsy and
stored at - 20°C.
Preparation ofa BSA-hapten conjugates
Tritium-labelled and unlabelled CCI-103F was reductively
bound to BSA by means of a published procedure for the
radiation chemical binding of 2-nitroimidazoles to thiol-rich
proteins (Raleigh & Koch, 1990). The tritiated CCI-
103F-BSA conjugate was used as a calibration standard for
the ELISA, while the unlabelled conjugate was used as a
solid phase, coating antigen in the competitive ELISA des-
cribed below. For the purpoose of conjugate preparation,
CCI-103F was reductively activated by electrons produced by
water radiolysis. Briefly, bovine serum albumin at 1 mg ml-'
was dissolved in 25 ml of 50 mM phosphate buffer (pH 7.5)
containing 100 mM sodium formate. The solution was
divided into 5 ml aliquots and each aliquot deoxygenated by
means of nitrogen gas flowing over the rapidly stirred solu-
tions for 60 min in five septum-sealed, 30 ml serum bottles.
The deoxygenated solutions were irradiated in a 13'CS gamma
source to 800 Gy in order to reduce some of the 34 disul-
phide moieties in BSA to thiol groups, which are known
to bind avidly to reductively activated 2-nitroimidazoles
(Raleigh & Koch, 1990). Typically, a protein thiol concentra-
tion of 200JAM as measured by Ellman's reagent (Ellman,
1959) was generated under the conditions used here. CCI-
103F or [3H]CCI-103F (specific activity = 52.8 JLCi mg-') was
then added to the irradiated BSA solutions. In both cases the
concentration of CCI-103F was 26.5 gM. The solutions were
deoxygenated as before and then irradiated to 24 Gy in order
to reductively activate CCI-103F or [3H]CCI-103F and cause
them to bind to the thiol groups in the BSA. Following
irradiation, the irradiated solutions were combined and an
excess of N-ethylmaleimide (5mg, 1.6mM) added to 'cap'
unreacted thiols on the BSA. It was calculated that 0.4
molecules of [3H]CCI-103F bound per molecule of BSA,
which is in close agreement with the finding that c. 20% of
reductively activated [3H]CCI-103F binds to thiol-rich BSA
under these conditions (Raleigh & Koch, 1990). It was
assumed that a similar degree of 'cold' CCI-103F binding to
BSA occurred. The combined solutions were then dialysed
and concentrated to 1.0 ml by means of diafiltration with an
Amicon Centriprep concentrator. The concentrated solutions
were stored at - 20°C.
ELISA of[3H]CCI-103F-labelled canine tissues
Weighed samples of canine liver or tumour tissue
(10-100 mg) containing covalently bound [3H]CCI-103F
were minced and suspended in 10 volumes of a phosphate-
buffered saline-0.05% Tween (PBS-Tween) solution in a
5 ml round-bottomed glass tube. The suspension was
thoroughly homogenised by means of an Omni Mixer fitted
with a Minimicro generator. At this point, an aliquot of the
homogenate was taken for protein determination by the BCA
reagent. For the ELISA measurement of tissue-bound CCI-
103F, the homogenates were diluted 1:1 with PBS-Tween
containing I mg ml-' proteinase K (20 unitsmg-') and the
mixture incubated overnight at 37°C in a shaking water bath.
The enzyme inhibitor, phenylmethylsulphonyl fluoride
(PMSF), was added at a final concentration of 200JAM and
the reaction mixture incubated for 5 min at room tem-
perature. For ELISA on tissues containing low concentra-
tions of bound CCI-103F, it was found necessary to add a
second aliquot of PMSF to a final concentration of 400JAM
followed by heating for 10 min at 95°C in a hot water bath in
order to completely inactivate the proteinase K. This proce-
dure was adopted for all samples. The digested sample was
centrifuged for 10 min at 10,000 r.p.m. in an Eppendorf
model 5415 microfuge in order to pellet particulate material.
For the ELISA, the calibration standards, whether tissue-
derived or synthetic BSA-CCI-103F conjugates, were hydro-
lysed with proteinase K and otherwise treated as the tumour
tissue samples. The material in the pellet formed by cen-
trifugation of the proteinase K digest tended to be fluffy and
could be dispersed by vortexing. However, as discussed
below, aliquots of the supernatant only were carefully drawn
off and used for the ELISA.
The supernatants from the homogenised, digested and cen-
trifuged samples were serially diluted in polyvinyl microassay
plate wells for preincubation with anti-CCI-103F rabbit
antiserum. To each of the 100ly samples in the wells was
added 25 1tl of anti-CCI-103F rabbit antiserum solution
diluted 1:200 in PBS-Tween. The plate was covered tightly
with Parafilm and incubated for 2 h at 37°C. The contents of
each well of the polyvinyl microassay plate were then trans-
ferred to the wells of polystyrene ELISA plates, the surfaces
of which had been coated with the solid phase CCI-103F
antigen bound to BSA. Uncoated surfaces had been blocked
against non-specific binding of the rabbit antiserum by a
treatment with 1% goat serum in PBS-Tween pH 7.4 for 2 h
at 37°C. In addition to standards, two test samples were
arranged in quadruplicate in each plate.
The competition between solid phase and soluble CCI-
103F antigens for the anti-CCI-103F rabbit antiserum was
allowed to proceed for 2 h at 37°C in the ELISA plates. The
wells were then washed four times with PBS-Tween and
100fsl of a working concentration of a 1:1000 alkaline phos-
phatase-conjugated, goat anti-rabbit IgG was added to each
well. Following a 2 h incubation at 37°C, the plates were
against washed four times with PBS-Tween and then three
times with 10% diethanolamine in water, pH 9.8. To each
well was added 50Jl of a 1 mg ml' solution of the alkaline
phosphatase substrate, 4-nitrophenyl phosphate, in 10%
diethanolamine. The development of colour at 405 nm was
followed by means of a Molecular Devices Vmax kinetic plate
reader. The data were analysed and plotted with the aid of A
Soft II Version 3.3. ELISAnalysis software (Biometallics) in
conjunction with a Macintosh Ilsi computer (Apple Com-
puter) and a Cricket Graph software package (Computer
Associates).
Selection and irradiation ofcanine tumours
Privately owned dogs with spontaneous tumours were
selected from the Oncology Service of the North Carolina
State University College of Veterinary Medicine. The dogs
remained the property of the owners. The study reported
here was approved by the Institutional Animal Care and Use
Committee of North Carolina State University. Tumour
types were confirmed by histopathology. A list of tumour
types used in the development stages of the ELISA technique
is given in Table I.
In one illustrative case of the application of ELISA to a
tumour undergoing radiation treatment, a scapular fibrosar-
coma was irradiated with cobalt-60 photons given in daily
(Monday to Friday) 3.0Gy fractions. The dog was under
general anaesthesia for biopsy and irradiation. Anaesthesia
was induced and maintained with isoflurane. The fractional
inspired oxygen value during irradiation was 100%. The dog68 J.A. RALEIGH et al.
Table I Binding ofCCI-103F to spontaneous canine tumours. ELISA
on multiple samples taken from widely separated regions ofthe excised
tumour masses
CCI-103F (ftmolkg-' tissue weight)
Tumour Mean ± s.d. (n; range)
Synovial sarcoma 9.7 ± 3.9 (n = 10; 4.3- 16)
Undifferentiated sarcoma 20.5 10.3 (n = 8; 9.9-23.7)
Lymphosarcoma 9.8 ± 2.7 (n = 6; 5.1-13.1)
Liposarcoma 34.7 ± 4.0 (n = 3; 29-38)
Undifferentiated sarcoma 58 ± 18.5 (n = 3; 37.5-73.5)
Mast cell 22.6 ± 9.2 (n = 3; 12.3-30)
Mast cell 45.8 ± 5.7 (n = 3; 39.6-50.7)
Oral carcinoma 25.6 ± 2.6 (n = 3; 22.8-27.9)
Rectal adenocarcinoma 11.7 (n = 2; 10.7-12.6)
Haemangiopericytoma 24.5 (n = 2; 12.6-36.3)
Mast cell 23.7 (n = 2; 18.6-28.8)
was under general anaesthesia for approximately 20 min for
each radiation fraction.
Labelling ofcanine tumours with CCI-103F
Either tritiated or unlabelled CCI-103F dissolved in 0.9%
saline at a concentration of 1.5 g -' was administered to the
dogs by way of the cephalic vein as a rapid intravenous
infusion of 5-O min duration. The CCI-103F solution was
filtered through a 0.2 ytm filter prior to injection. Two types
of experiment were performed.
In one type of experiment (Table I), tumours were excised
and frozen for subsequent ELISA analysis. In a second type
of experiment involving unlabelled CCI-103F only (Table II),
CCI-103F was injected and 24 h later - just before the first
dose of fractionated 'Co gamma-irradiation - two 50 mg
biopsy samples were taken from different regions of the
canine tumour by means of a 14 gauge Trucut needle. All
biopsies were carried out under aseptic conditions. Addi-
tional paired biopsies were taken at 72 h after the injection of
CCI-103F in order that the kinetics of the loss of tissue-
bound CCI-103F might be estimated. The second injection of
CCI-103F occurred just before the sixth dose of 3 Gy. A
weekend intervened in the treatment so that the biopsies were
taken on day 8, at which time the dog had received 15 Gy of
radiation. The biopsy procedure for the first injection was
repeated for the second injection.
Table II ELISA of CCI-103F binding to a canine scapular
fibrosarcoma. The distribution ofCCI-103F binding in a biopsy ofthis
tumourisshownin Figure 3. FortheELISA,pairedbiopsiesweretaken
atintervals of24 haftertheinjectionofCCI-103F. Theresultsaregiven
as average tissue concentrations with individual biopsy results given in
parentheses. In each case, the biopsies were taken just prior to the
irradiation for the day. ELISA of the biopsies 72 h after the first
injection shows the loss of tissue-bound CCI-103F. No biopsies were
taken 48 h after the first injection of CCI-103F. On day 8, paired
biopsies weretaken 24 hafterthesecondinjectionofCCI-103Fandjust
priorto thesixthirradiation(accumulated dose = 15 Gy). Biopsiesat48
and 72 h show the loss of CCI-103F from the tumour tissue following
the second injection of CCI-103F. The measured intensities for
CCI-103F binding are corrected for the difference between BSA and
tissue-derived standards (see text)
Hours post Accumulated dose CCI-103Fbound
Biopsies CCI-103F injection (Gy) (pmolkg-')
First CCI-103F injection (day preceding thefirst dose ofradiation)
1 and 2 24 0 17.1 (13, 21.1)
3 and 4 72 10 2.5 (2.4, 2.5)
Second CCI-103F injection (8 days after thefirst injection)
5 and 6 24 15 10.7 (8.7, 12.4)
7 and 8 48 20 6.8 (6.2, 7.4)
9 and 10 72 25 4.1 (3.4, 4.7)
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Results
ELISA calibration
The curves resulting from semilog plots of the ELISA data in
optical density units per minute at 405 nm (p-nitrophenolate)
against CCI-103F concentrations as determined by scintilla-
tion counting of samples prepared with [3H]CCI-103F were
parallel for tumour tissue, liver tissue and the BSA-[3H]CCI-
103F standard (Figure 1). The curve for the BSA standard
was found to be shifted to the left of both liver and tumour
tissues. In five independent experiments, the haptens derived
from the BSA-[3H]CCI-103F standard by proteinase K
digestion were found to be 2.2 ± 0.1 times more effective in
inhibiting the binding of anti-CCI-103F rabbit antiserum to
solid phase antigens than were those derived from the liver
tissue adducts of CCI-103F which were formed by the in vivo
labelling of dog tissues with [3H]CCI-103F. When a similar
comparison was made between the BSA-[3H]CCI-103F stan-
dard and the antigens derived from five different biopsy
samples of tumour tissue from the same dog the ratio was
2.0 ± 0.4. The tumour tissue data were less reproducible but
not significantly different from the liver data. The data points
for free CCI-103F fall to the right of tumour, liver and BSA
curves (Figure 2).
Figure 1 Enzyme-linked immunosorbent assay of the super-
natants of the proteinase K digests of [3H]CCI-103F-labelled liver
tissue and tumour tissues (0) and [3H]CCI-103F-BSA adduct
(0). The combined liver and tumour tissue data represent the
result from a total of six different tissue samples examined in the
same experiment.
Distribution of[3HJCCI-103F-derived adducts in canine tissue
After centrifugation of proteinase K digests of homogenates
from radioactively labelled tissues, it was found that antigens
formed from reductively activated [3H]CCI-103F were dis-
tributed between the supernatant and pelleted material. In
the homogeneous liver tissue samples, the pellets were of
uniform size and the distribution of ['H]CCI-103F binding
was reproducible with 75% appearing in the supernatant and
25% in the pellet. The size of the pellets from digests of the
tumour tissue homogenates was more variable and lesser
amounts of binding ranging from 0 to 6% were seen in the
pellets. Various combinations of sonication, heating and
digestion with hyaluronidase (2.0 mgml'), elastase (2.5 mg
ml-'), collagenase (5.0 mgml-') or DNA phosphodiesterase
(5.0 mgml-') increased solubilisation of the pelleted radio-
activity either marginally or not at all (data not shown).
Radioactivity associated with the pellets was totally soluble
in acetone or chloroform. With this in mind, it was found
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The results of a typical biopsy-based study in which, unlike
the experiment of Table I, the tumour was not excised are
reported in Table II. Both the intensity of CCI-103F binding
to the tumour 24 h after CCI-103F injection and the subse-
quent elimination of bound CCI-103F from the tumour
tissue was measured by ELISA on biopsy samples taken
from a large scapular fibrosarcoma. A tissue section of a
biopsy sample taken from this tumour and immunostained
with a peroxidase-anti-peroxidase procedure (Cline et al.,
1990) is shown in Figure 3. The intensities of CCI-103F
binding are given in the table as averages of binding in
paired biopsies. In this experiment, the [3H]CCI-103F-BSA
adduct was used as the standard on the ELISA microtitre
plates and a correction made for the difference between the
BSA and tissue-derived CCI-103F antigens (factor of 2.2).
For reasons discussed below, the concentration of tissue-
bound CCI-103F is given in terms of the tissue weight. It was
found that CCI-103F concentrations expressed in terms of
either tissue weight or protein content are correlated (Figure
4).
10-2 10-1 100 10l 102 103 104 105
[CCI-103F hapten] (nM)
Figure 2 Enzyme-linked immunosorbent assay of free CCI-103F
(M); the supernatants from proteinase K digests of a [3H]CCI-
103F-liver homogenate (0); a [3H]CCI-103F-tumour homogenate
(M) and [3H]CCI-103F-BSA (0).
that a 2:1 chloroform-methanol solvent extracted 30% of
the radioactivity from the liver homogenate prior to pro-
teinase K digestion, which was close to the amount of
radioactivity found in pellets after centrifugation of the pro-
teinase K digest of the liver tissue homogenate (see above).
Chloroform-methanol extracts of tumour homogenates, liver
homogenates and chloroform extracts of the pellets formed
in the proteinase K digest of the tissue homogenates behaved
in the same way upon TLC analysis (data not shown). In
these cases, radioactivity was concentrated on the TLC plate
in a few major bands which contained materials more polar
than cholesterol but less polar than phosphatidylcholine. The
mixed, 2:1 chloroform-methanol solvent extracted very little
radioactivity (c. 8%) from the supernatant of the proteinase
K digests. Owing to the small amount of radioactivity, a
TLC analysis of this extract was not possible. Further
attempts to identify the CCI-103F-conjugated lipids has not
been made. It was noted in the TLC analyses that essentially
no radioactivity appeared where unchanged CCI-103F
migrated.
The addition of 1.2% Triton X-100 to the tissue
homogenates with proteinase K was effective in solubilising
c. 98% of the radioactivity derived from tissue-bound
[3H]CCI-103F, but this procedure significantly lowered the
sensitivity of the ELISA. Furthermore, the amount of CCI-
103F bound to the particulate matter in the proteinase K
digest of the tumour tissue as distinct from that of the liver
tissue was small. Therefore, for the purposes of the present
study, the ELISA was restricted to an analysis of the super-
natant of the proteinase K digest of the homogenates.
ELISA measurement ofCCI-103Fbinding to canine tumours
In a preliminary study, multiple small tissue samples were
taken from a variety of excised tumours and analysed by
ELISA in an attempt to address the question of how
representative biopsy samples might be. The results are sum-
marised in Table I. In those cases where three or more
samples (n = 3 to n = 10) from a single tumour were
analysed, the standard deviation of the mean ranged from
9% to 50%.
Figure 3 Immunostaining of a tissue section prepared from a
Trucut biopsy taken from a canine scapular fibrosarcoma 24 h
after the first injection of CCI-103F. ELISA data for this tumour
are presented in Table II. Magnification x 100.
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Figure 4 Correlation between concentrations of tissue-bound
CCI-103F given as either jmol kg- ' tissue weight or ltmol kg-'
protein in the tumour tissue biopsies. A best-fit straight line is
drawn through the data points (y = 13.4x + 10.4, correlation
coefficient = 0.77).
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Discussion
Enzyme-linked immunosorbent assay of tissue haptens is
generally directed at a specific chemical structure. However,
in the case of the reductive binding of 2-nitroimidazoles to
macromolecules in hypoxic cells, the structure of the hapten
is imperfectly known. Studies with the radioactively labelled
2-nitroimidazole, misonidazole, have shown that its binding
to hypoxic rodent tissue and cells is predominantly to pro-
teins (c. 75%) (Smith, 1984) with only small amounts to
lipids (c. 2%) (Miller et al., 1982) and nucleic acids (c. 4%)
(Smith, 1984). Protein thiols are particularly efficient at bind-
ing reductively activated 2-nitroimidazoles, including mis-
onidazole and CCI-103F (Raleigh & Koch, 1990). On this
basis, it seems reasonable to assume that the majority of
CCI-103F tumour tissue adducts have structures similar to
those for the thiol tripeptide, glutathione, in which reduc-
tively activated misonidazole is adducted to a thiol moiety
through the 4 or 5 position of the imidazole structurre (Var-
ghese, 1983; Chacon et al., 1988). Consistent with this
assumption is the fact that synthetic antigens generated by
the binding of reductively activated CCI-103F to thiol-rich
BSA in test tube experiments are excellent solid phase
antigens in the competitive ELISA for the analysis of tissue-
bound CCI-103F.
It is well known that hypoxia marker binding occurs to
liver tissue (Cobb et al., 1992; Van Os-Corby et al., 1987)
and [3H]CCI-103F-labelled liver tissue was seen as a useful
source ofmaterial for calibrating the ELISA. The antisera to
CCI-103F were known to respond strongly to the hexafluor-
inated side chain of CCI-103F (Raleigh et al., 1987) so that
the precise structure of the hapten at the point of linkage to
macromolecules might have been relatively unimportant for
the ELISA. However, the antigen derived from protein- bound CCI-103F was, in fact, 20 (tissue) to 45 (BSA) times
better as a competitive inhibitor than was free CCI-103F. In
addition, the sensitivity of the ELISA to hapten structure
was further revealed in the distinction between BSA and
tissue-derived antigens (Figure 2). This brings into question the use of tritium-labelled liver tissue as a calibration stan-
dard given the somewhat surprising result that 25-30% of
the CCI-103F binding was to lipid components in the liver
tissue. The problem was avoided by analysing the super-
natant only of the proteinase K digest in which very little, if
any, of the lipid antigen was present. Importantly, the bind-
ing of CCI-103F to lipid components in tumour tissue was
very much lower than that observed for the dog liver. Fur-
thermore, the differential response between tissue antigens and BSA antigens in the proteinase K digests was the same
for both liver and tumour tissues (Figure 1). Future improve-
ments in the ELISA for tissue-bound CCI-103F could
include an analysis of a completely solubilised tissue
homogenate, but the convenient approach ofmeasuring CCI-
103F binding in the supernatant of the proteinase K digest alone without attempting to include contributions from the
lipid-containing pellet was considered adequate for our pur-
poses. It should be noted that the relative insensitivity of the
ELISA to free CCI-103F has the practical advantage that
low levels of residual, unbound CCI-103F in the tumour
tissues will not interfere with the analysis of tissue-bound
CCI-103F.
In physically non-invasive, volume-averaged analyses of
hypoxia marker binding by '9F-MRS, SPECT or PETT,
access to tissue protein content is not available and it seemed
appropriate to express the volume-averaged concentration of
tissue-bound CCI-103F measured by ELISA in terms of
tissue volume or weight even though tissue protein might be
a major site of CCI-103F binding. In fact, the concentration
of tissue-bound CCI-103F expressed as Amol per kg of pro- tein can be directly correlated with that measured as .tmol
per kg tissue weight (Figure 4). The relative intensities of
CCI-103F binding reported in Table IIare not significantly changed when calculations are carried out on the basis of
Amol per kg ofprotein rather thanl.mol per kg tissue weight. The ELISA measurement of CCI-103F binding in multiple
biopsies can be expected to suffer from the usual sampling
errors of a biopsy-based technique. Nevertheless, the results
in Tables I and II indicate that reasonably repeatable biopsy
results can be achieved. It should be emphasised that the
important parameter in Table II with respect to changes in
tumour hypoxia is the intensity of binding 24 h after the first
and second injection of the marker and not the kinetics of
the loss of the signal after each injection. Furthermore, the
choice of assaying hypoxia marker binding after 5 x 3 Gy of
irradiation treatment was arbitrary, being designed primarily
to test the feasibility of the procedure. It is yet to be deter-
mined when the optimum time for reassessing marker bind-
ing is with respect to following the process of reoxygenation
and/or relating binding to treatment outcome.
Qualitatively, the kinetics of decay of the tissue-bound
CCI-103F is such that reinjection of the same marker can be
contemplated on a 7 day cycle without interference from
previous injections (Table II). We cannot yet calculate with
any degree of accuracy the half-life for signal decay after
injection, nor is it known whether radiation treatment
interferes in any way with elimination of the tissue-bound
CCI-103F from the tumours. Studies of these questions are
under way in rodents in order to compare the characteristics
of CCI-103F elimination with those of the less lipophilic [I4C]misonidazole (Garrecht & Chapman, 1983), in which
case a long half-life for signal decay (c. 50 h) in the terminal
phase was observed in unirradiated mouse tumours.
To date, our use of the calibrated ELISA in analysing
CCI-103F binding in spontaneous tumours in 12 canine
patients along the lines of the data presented in Table II
indicates that the inherent intensity of hypoxia marker bind-
ing prior to treatment varies by a factor ofapproximately 25
(D.E. Thrall et al., in preparation). The high sensitivity ofthe
ELISA may account for our ability to detect binding in most
of the spontaneous canine tumours and to detect binding
over a wide range of intensities. A somewhat narrower range
of binding intensities was observed in clinical investigations
with tritium-labelled misonidazole (Urtasun et al.,1986). In
the Urtasun et al. study, semiquantitative comparisons
between histological measurements (autoradiographic 'zones
of dense labelling') and volume-averaged measurements
based on scintillation counting of digested pieces of tumour
tissue ('tumour/plasma ratios') showed that, for tumours pos-
sessing zones of dense labelling, the intensity of binding
based on tumour to plasma ratios varied by a factor of c. 7
(Chapman, 1991). Smaller ranges of binding intensities of
2-3 were observed for transplanted murine tumours possess-
ing the similar hypoxic fractions (Franko, 1986; Hirst et al.,
1985).
While binding intensity in experimental tumours of a single
type can be directly related to radiobiological hypoxic frac-
tion or radiation response (Hirst et al., 1985; Li et al., 1991),
the wide range of binding intensities among spontaneous
tumours provides little hope that binding intensities as
measured by volume-averaged assays such as ELISA, PETT,
SPECT or '9F-MRS will provide a measure of absolute
hypoxic fractions in a clinical setting. Volume-averaged
measurements of binding intensity could, however, be a
valuable way of following changes in hypoxic fraction during
tumour treatment. Each tuimour would serve as its own
control and automatically take into account factors such as
inherent binding capacity, oxygen dependence of binding,
binding to stromal tissue, etc. (Franko et al., 1987). The
value of the immunochemical approach in this context is that
a single set of reagents provides for a rapid and inexpensive
means of following changes in hypoxia marker binding
(ELISA), which can be related to the fraction of cells binding
the marker (immunohistochemical analysis) in the same
biopsy samples (Cline et al., 1990). The high sensitivity of the
ELISA should allow for the analysis of very low residual
levels of hypoxia marker binding in a shrinking tumour. Of
course, the untested assumption in these studies is that the
inherent hypoxia marker-binding capacity of the tumour cells
remains unchanged during treatment.
In summary, knowledge of the exact chemical nature ofELISA FOR HYPOXIA MARKER BINDING 71
the hypoxia marker antigens does not appear to be critical
for the purposes of ELISA measurement of the relative inten-
sities of hypoxia marker binding in tumour tissue. While the
ELISA described here was calibrated against both synthetic
and tissue-derived antigens, the synthetic antigen derived
from BSA is easier to generate and ultimately could be
prepared in a non-radioactive form. The response of the
synthetic antigen in the ELISA appears to be different from
that of the tissue-derived antigen and, in those cases where
an estimate of the absolute amount of CCI-103F bound to
tissue is desired, the synthetic standard appears to under-
estimate the amount of CCI-103F bound in vivo. A correc-
tion factor can be applied to account for the difference
which, in our particular case, is 2.2. The ELISA has been
successfully applied to following changes in hypoxia marker
binding during radiation therapy without the need for
radioactive reagents being injected into the canine patients.
The ELISA has the advantages in a clinical setting of being
very sensitive, dependent on routine tumour biopsy and
ELISA procedures and well adapted to the rapid analysis of
multiple samples generated by multiple biopsy samples dur-
ing a course of radiation treatment. Ultimately, a combina-
tion of immunohistochemical analysis and ELISA might
prove to be an effective way of estimating tumour hypoxia
and its changes during therapy.
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